2023 Guidance and Q3 Earnings
Q3 2022
£m
2.605
Net finance expense
(177)
Improved adj. earnings per share, with 17% CER growth
Adj. operating profit (OP)
Key commentary
+15% at CER, +22% (at CER excluding COVID-19 solutions)
Lower bond interest costs and higher interest income
Q3 2023
£m
2,772
(156)
Share of associates
(1)
Ταχ
(402)
(404)
Tax rate
16.6%
15.4%
Non-controlling interests
(135)
(169)
Timing of tax settlements relative to Q3 2022
NCIS allocation of higher ViiV Healthcare profits
Profit attributable to shareholders
1,890
2,043
Adj. earnings per share (EPS)
46.9p
50.4p
+17% at CER, +25% (at CER excluding COVID-19 solutions)
Total EPS
18.8p
36.1p
+>100% at CER
Weighted average number of shares (millions)
4,030
4,055
GSK
Adjusted results and for continuing operations unless stated otherwise
24View entire presentation